Risk stratification in normotensive acute pulmonary embolism patients: focus on the intermediate–high risk subgroup. Issue 4 (June 2020)
- Record Type:
- Journal Article
- Title:
- Risk stratification in normotensive acute pulmonary embolism patients: focus on the intermediate–high risk subgroup. Issue 4 (June 2020)
- Main Title:
- Risk stratification in normotensive acute pulmonary embolism patients: focus on the intermediate–high risk subgroup
- Authors:
- Santos, Ana Rita
Freitas, Pedro
Ferreira, Jorge
Oliveira, Afonso
Gonçalves, Mariana
Faria, Daniel
Bicho Augusto, João
Simões, Joana
Santos, Ana
Gago, Miguel
Oliveira, João
Antunes, Ricardo Mamede
Correia, David
Lynce, Ana
Brito, João
Morais, Carlos
Campos, Luís
Mendes, Miguel - Abstract:
- Background: Patients with acute pulmonary embolism are at intermediate–high risk in the presence of imaging signs of right ventricular dysfunction plus one or more elevated cardiac biomarker. We hypothesised that intermediate–high risk patients with two elevated cardiac biomarkers and imaging signs of right ventricular dysfunction have a worse prognosis than those with one cardiac biomarker and imaging signs of right ventricular dysfunction. Methods: We analysed the cumulative presence of cardiac biomarkers and imaging signs of right ventricular dysfunction in 525 patients with intermediate risk pulmonary embolism (intermediate-high risk = 237) presenting at the emergency department in two centres. Studied endpoints were composites of all-cause mortality and/or rescue thrombolysis at 30 days (primary endpoint; n =58) and pulmonary embolism-related mortality and/or rescue thrombolysis at 30 days (secondary endpoint; n =40). Results: Patients who experienced the primary endpoint showed a higher proportion of elevated troponin (47% vs. 76%, P <0.001), elevated N-terminal pro-brain natriuretic peptide (67% vs. 93%, P <0.001) and imaging signs of right ventricular dysfunction (47% vs. 80%, P <0.001). Multivariate analysis revealed N-terminal pro-brain natriuretic peptide (hazard ratio (HR) 3.6, 95% confidence interval (CI) 1.3–10.3; P =0.015) and imaging signs of right ventricular dysfunction (HR 2.8, 95% CI 1.5–5.2; P =0.001) as independent predictors of events. In theBackground: Patients with acute pulmonary embolism are at intermediate–high risk in the presence of imaging signs of right ventricular dysfunction plus one or more elevated cardiac biomarker. We hypothesised that intermediate–high risk patients with two elevated cardiac biomarkers and imaging signs of right ventricular dysfunction have a worse prognosis than those with one cardiac biomarker and imaging signs of right ventricular dysfunction. Methods: We analysed the cumulative presence of cardiac biomarkers and imaging signs of right ventricular dysfunction in 525 patients with intermediate risk pulmonary embolism (intermediate-high risk = 237) presenting at the emergency department in two centres. Studied endpoints were composites of all-cause mortality and/or rescue thrombolysis at 30 days (primary endpoint; n =58) and pulmonary embolism-related mortality and/or rescue thrombolysis at 30 days (secondary endpoint; n =40). Results: Patients who experienced the primary endpoint showed a higher proportion of elevated troponin (47% vs. 76%, P <0.001), elevated N-terminal pro-brain natriuretic peptide (67% vs. 93%, P <0.001) and imaging signs of right ventricular dysfunction (47% vs. 80%, P <0.001). Multivariate analysis revealed N-terminal pro-brain natriuretic peptide (hazard ratio (HR) 3.6, 95% confidence interval (CI) 1.3–10.3; P =0.015) and imaging signs of right ventricular dysfunction (HR 2.8, 95% CI 1.5–5.2; P =0.001) as independent predictors of events. In the intermediate–high risk group, patients with two cardiac biomarkers performed worse than those with one cardiac biomarker (HR 3.3, 95% CI 1.8–6.2; P =0.003). Conclusions: Risk stratification in normotensive pulmonary embolism should consider the cumulative presence of cardiac biomarkers and imaging signs of right ventricular dysfunction, especially in the intermediate–high risk subgroup. … (more)
- Is Part Of:
- European heart journal. Volume 9:Issue 4(2020)
- Journal:
- European heart journal
- Issue:
- Volume 9:Issue 4(2020)
- Issue Display:
- Volume 9, Issue 4 (2020)
- Year:
- 2020
- Volume:
- 9
- Issue:
- 4
- Issue Sort Value:
- 2020-0009-0004-0000
- Page Start:
- 279
- Page End:
- 285
- Publication Date:
- 2020-06
- Subjects:
- Pulmonary embolism -- risk assessment -- biomarkers -- troponin -- NT-proBNP
616.1205 - Journal URLs:
- https://academic.oup.com/ehjacc/issue ↗
http://acc.sagepub.com/ ↗
http://www.uk.sagepub.com/home.nav ↗ - DOI:
- 10.1177/2048872619846506 ↗
- Languages:
- English
- ISSNs:
- 2048-8726
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 14005.xml